Molecular Neuropsychiatry最新文献

{"title":"Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.","authors":"Bharathi S Gadad,&nbsp;Prithvi Raj,&nbsp;Manish K Jha,&nbsp;Thomas Carmody,&nbsp;Igor Dozmorov,&nbsp;Taryn L Mayes,&nbsp;Edward K Wakeland,&nbsp;Madhukar H Trivedi","doi":"10.1159/000487321","DOIUrl":"https://doi.org/10.1159/000487321","url":null,"abstract":"<p><p>Genome-wide association studies (GWAS) were conducted in participants of the CO-MED (Combining Medications to Enhance Depression Outcomes) trial, a randomized, 3-treatment arm clinical trial of major depressive disorder (MDD) designed to identify markers of differential treatment outcome (response and remission). The QIDS-SR (Quick Inventory of Depressive Symptomatology, Self-Reported version) was used to measure response at week 6 (QIDS-SR ≤5) and remission at week 12 (QIDS-SR ≤6 and ≤8 at the last two study visits). Three treatment groups (escitalopram monotherapy, escitalopram + bupropion, and venlafaxine + mirtazapine) were evaluated. GWAS identified a potentially regulatory SNP rs10769025 in the ALX4 gene on chromosome 11 with a strong association (<i>p</i> value = 9.85925E-08) with response to escitalopram monotherapy in Caucasians. Further, haplotype analysis on 7 ALX4 variants showed that a regulatory haplotype CAAACTG was significantly associated (odds ratio = 3.4, <i>p</i> = 2.00E-04) with response to escitalopram monotherapy at week 6. Ingenuity pathway analyses in the present study suggest that ALX4 has an indirect connection with antidepressant gene pathways in MDD, which may account for the genetic association with treatment outcome. Functional genomics studies to investigate the role of ALX4 in antidepressant treatment outcome will be an interesting future direction.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 1","pages":"7-19"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000487321","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Complex Interaction of Mitochondrial Genetics and Mitochondrial Pathways in Psychiatric Disease.","authors":"Ari B Cuperfain,&nbsp;Zhi Lun Zhang,&nbsp;James L Kennedy,&nbsp;Vanessa F Gonçalves","doi":"10.1159/000488031","DOIUrl":"https://doi.org/10.1159/000488031","url":null,"abstract":"<p><p>While accounting for only 2% of the body's weight, the brain utilizes up to 20% of the body's total energy. Not surprisingly, metabolic dysfunction and energy supply-and-demand mismatch have been implicated in a variety of neurological and psychiatric disorders. Mitochondria are responsible for providing the brain with most of its energetic demands, and the brain uses glucose as its exclusive energy source. Exploring the role of mitochondrial dysfunction in the etiology of psychiatric disease is a promising avenue to investigate further. Genetic analysis of mitochondrial activity is a cornerstone in understanding disease pathogenesis related to metabolic dysfunction. In concert with neuroimaging and pathological study, genetics provides an important bridge between biochemical findings and clinical correlates in psychiatric disease. Mitochondrial genetics has several unique aspects to its analysis, and corresponding special considerations. Here, we review the components of mitochondrial genetic analysis - nuclear DNA, mitochon-drial DNA, mitochondrial pathways, pseudogenes, nuclear-mitochondrial mismatch, and microRNAs - that could contribute to an observable clinical phenotype. Throughout, we highlight psychiatric diseases that can arise due to dysfunction in these processes, with a focus on schizophrenia and bipolar disorder.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 1","pages":"52-69"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dominant-Negative DISC1 Alters the Dopaminergic Modulation of Inhibitory Interneurons in the Mouse Prefrontal Cortex.","authors":"Ross A Cardarelli,&nbsp;Rolicia Martin,&nbsp;Hanna Jaaro-Peled,&nbsp;Akira Sawa,&nbsp;Elizabeth M Powell,&nbsp;Patricio O'Donnell","doi":"10.1159/000488030","DOIUrl":"https://doi.org/10.1159/000488030","url":null,"abstract":"<p><p>A truncated <i>disrupted in schizophrenia 1</i> (<i>Disc1</i>) gene increases the risk of psychiatric disorders, probably affecting cortical interneurons. Here, we sought to determine whether this cell population is affected in mice carrying a truncated (<i>Disc1</i>) allele (DN-DISC1). We utilized whole cell recordings to assess electrophysiological properties and modulation by dopamine (DA) in two classes of interneurons: fast-spiking (FS) and low threshold-spiking (LTS) interneurons in wild-type and DN-DISC1 mice. In DN-DISC1 mice, FS interneurons, but not LTS interneurons, exhibited altered action potentials. Further, the perineuronal nets that surround FS interneurons exhibited abnormal morphology in DN-DISC1 mice, and the DA modulation of this cell type was altered in DN-DISC1 mice. We conclude that early-life manipulation of a gene associated with risk of psychiatric disease can result in dysfunction, but not loss, of specific GABAergic interneurons. The resulting alteration of excitatory-inhibitory balance is a critical element in DISC1 pathophysiology.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 1","pages":"20-29"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Further Evidence of an Association between <i>NCAN</i> rs1064395 and Bipolar Disorder.","authors":"Lu Wang,&nbsp;Weiqing Liu,&nbsp;Xingxing Li,&nbsp;Xiao Xiao,&nbsp;Lingyi Li,&nbsp;Fang Liu,&nbsp;Yuanfang He,&nbsp;Yan Bai,&nbsp;Hong Chang,&nbsp;Dong-Sheng Zhou,&nbsp;Ming Li","doi":"10.1159/000488590","DOIUrl":"https://doi.org/10.1159/000488590","url":null,"abstract":"<p><p>Genome-wide association studies suggest that rs1064395 in the neurocan gene (<i>NCAN</i>) is a potential risk factor for bipolar disorder (BPD), and further replication analyses in larger independent samples are needed. We herein analyzed rs1064395 in a Han Chinese sample of 1,146 BPD cases and 2,031 controls, followed by a meta-analysis of BPD samples from worldwide populations including a total of 15,318 cases and 91,990 controls. The meta-analysis found that rs1064395 showed a genome-wide significant association with BPD (<i>p</i> = 4.92 × 10^-9, OR = 1.126 for the A allele), although it did not reach the significance level in the Han Chinese sample (<i>p</i> = 0.415, OR = 1.070 for the A allele). We also examined the association between the single nucleotide polymorphisms and major depressive disorder (MDD) given the presumed genetic overlap between BPD and MDD, and rs1064395 was also associated with MDD (<i>p</i> = 0.0068, OR = 1.067 for the A allele) in a meta-analysis of 14,543 cases and 14,856 controls. Our data provide further evidence for the involvement of <i>NCAN</i> in the genetic susceptibility to BPD and also implicate its broader role in major mood disorders.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 1","pages":"30-34"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in the Genetics of Schizophrenia.","authors":"Dimitrios Avramopoulos","doi":"10.1159/000488679","DOIUrl":"10.1159/000488679","url":null,"abstract":"<p><p>The last decade brought tremendous progress in the field of schizophrenia genetics. As a result of extensive collaborations and multiple technological advances, we now recognize many types of genetic variants that increase the risk. These include large copy number variants, rare coding inherited and de novο variants, and over 100 loci harboring common risk variants. While the type and contribution to the risk vary among genetic variants, there is concordance in the functions of genes they implicate, such as those whose RNA binds the fragile X-related protein FMRP and members of the activity-regulated cytoskeletal complex involved in learning and memory. Gene expression studies add important information on the biology of the disease and recapitulate the same functional gene groups. Studies of alternative phenotypes help us widen our understanding of the genetic architecture of mental function and dysfunction, how diseases overlap not only with each other but also with non-disease phenotypes. The challenge is to apply this new knowledge to prevention and treatment and help patients. The data generated so far and emerging technologies, including new methods in cell engineering, offer significant promise that in the next decade we will unlock the translational potential of these significant discoveries.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 1","pages":"35-51"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032037/pdf/mnp-0004-0035.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder.","authors":"Marquis Philip Vawter,&nbsp;Robert Philibert,&nbsp;Brandi Rollins,&nbsp;Patricia L Ruppel,&nbsp;Terry W Osborn","doi":"10.1159/000485800","DOIUrl":"https://doi.org/10.1159/000485800","url":null,"abstract":"<p><p>This study developed potential blood-based biomarker tests for diagnosing and differentiating schizophrenia (SZ), bipolar disorder type I (BD), and normal control (NC) subjects using mRNA gene expression signatures. A total of 90 subjects (<i>n</i> = 30 each for the three groups of subjects) provided blood samples at two visits. The Affymetrix exon microarray was used to profile the expression of over 1.4 million probesets. We selected potential biomarker panels using the temporal stability of the probesets and also back-tested them at two different visits for each subject. The 18-gene biomarker panels, using logistic regression modeling, correctly differentiated the three groups of subjects with high accuracy across the two different clinical visits (83-88% accuracy). The results are also consistent with the actual data and the \"leave-one-out\" analyses, indicating that the models should be predictive when applied to independent data cohorts. Many of the SZ and BD subjects were taking antipsychotic and mood stabilizer medications at the time of blood draw, raising the possibility that these drugs could have affected some of the differential transcription signatures. Using an independent Illumina data set of gene expression data from antipsychotic medication-free SZ subjects, the 18-gene biomarker panels produced a receiver operating characteristic curve accuracy greater than 0.866 in patients that were less than 30 years of age and medication free. We confirmed select transcripts by quantitative PCR and the nCounter® System. The episodic nature of psychiatric disorders might lead to highly variable results depending on when blood is collected in relation to the severity of the disease/symptoms. We have found stable trait gene panel markers for lifelong psychiatric disorders that may have diagnostic utility in younger undiagnosed subjects where there is a critical unmet need. The study requires replication in subjects for ultimate proof of the utility of the differential diagnosis.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"3 4","pages":"197-213"},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000485800","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36209634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear Receptors and Neuroinflammation in Schizophrenia.","authors":"Shan-Yuan Tsai,&nbsp;Vibeke S Catts,&nbsp;Janice M Fullerton,&nbsp;Susan M Corley,&nbsp;Stuart G Fillman,&nbsp;Cynthia Shannon Weickert","doi":"10.1159/000485565","DOIUrl":"https://doi.org/10.1159/000485565","url":null,"abstract":"<p><strong>Introduction: </strong>Several nuclear receptor family members have been associated with schizophrenia and inflammation. Vitamins A and D exert anti-inflammatory actions, but their receptors (mainly nuclear receptors) have not been extensively studied in either schizophrenia brains or in association with neuroinflammation. We examined the expression of vitamin A (RARs and RXRs) and vitamin D and protein disulphide-isomerase A3 (PDIA3) receptors, as well as nuclear orphan receptors (NR4As), in the context of elevated cytokine expression in the dorsolateral prefrontal cortex (DLPFC).</p><p><strong>Methods: </strong>mRNA levels of nuclear receptors were measured in DLPFC tissues via RT-qPCR. ANCOVAs comparing high inflammation schizophrenia, low inflammation schizophrenia and low inflammation control groups were performed.</p><p><strong>Results: </strong>RARG, RXRB, NR4A1 and NR4A3 transcripts showed significant differential expression across the three groups (ANCOVA p = 0.02-0.001). Post hoc testing revealed significant reductions in RARG expression in schizophrenia with low inflammation compared to schizophrenia with high inflammation and to controls, and RXRB mRNA was significantly reduced in schizophrenia with low inflammation compared to controls. NR4A1 and NR4A3 mRNAs were decreased in schizophrenia with high inflammation compared to schizophrenia with low inflammation, with NR4A1 also significantly different to controls.</p><p><strong>Conclusion: </strong>In schizophrenia, changes in nuclear receptor mRNA levels involved with mediating actions of vitamin A derivatives vary according to the inflammatory state of brains.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"3 4","pages":"181-191"},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000485565","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36210221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front & Back Matter","authors":"C. Barr, D. Mathalon, T. Petryshen","doi":"10.1159/000490009","DOIUrl":"https://doi.org/10.1159/000490009","url":null,"abstract":"","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82543913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 3, 2017","authors":"D. Mathalon, T. Petryshen, C. Abdallah, K. Brennand, E. Brietzke, A. Buonanno, Joao Luciano De Quevedo, M. Filiou, S. Hyman, A. Jaffé, M. Johnstone, Rakesh Karmacharya, T. Kash, J. Kelsoe, James L. Kennedy, Bryan W. Luikart, R. Malenka, A. Malhotra","doi":"10.1159/000489143","DOIUrl":"https://doi.org/10.1159/000489143","url":null,"abstract":"","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"22 1","pages":"I - IV"},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74869691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.","authors":"Thomas W Sedlak, Leslie G Nucifora, Minori Koga, Lindsay S Shaffer, Cecilia Higgs, Teppei Tanaka, Anna M Wang, Jennifer M Coughlin, Peter B Barker, Jed W Fahey, Akira Sawa","doi":"10.1159/000487639","DOIUrl":"10.1159/000487639","url":null,"abstract":"<p><p>Schizophrenia and other neuropsychiatric disorders await mechanism-associated interventions. Excess oxidative stress is increasingly appreciated to participate in the pathophysiology of brain disorders, and decreases in the major antioxidant, glutathione (GSH), have been reported in multiple studies. Technical cautions regarding the estimation of oxidative stress-related changes in the brain via imaging techniques have led investigators to explore peripheral GSH as a possible pathological signature of oxidative stress-associated brain changes. In a preclinical model of GSH deficiency, we found a correlation between whole brain and peripheral GSH levels. We found that the naturally occurring isothiocyanate sulforaphane increased blood GSH levels in healthy human subjects following 7 days of daily oral administration. In parallel, we explored the potential influence of sulforaphane on brain GSH levels in the anterior cingulate cortex, hippocampus, and thalamus via 7-T magnetic resonance spectroscopy. A significant positive correlation between blood and thalamic GSH post- and pre-sulforaphane treatment ratios was observed, in addition to a consistent increase in brain GSH levels in response to treatment. This clinical pilot study suggests the value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences sulforaphane has on functional measures that are altered in neuropsychiatric disorders.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"3 4","pages":"214-222"},"PeriodicalIF":0.0,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981770/pdf/mnp-0003-0214.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36209635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}